Routinely adding ultrasound to screening for breast cancer for women with dense breasts is not cost-effective.
Supplemental ultrasonography screening for women with dense breasts would substantially increase costs while producing relatively small benefits, according to a study published in the Annals of Internal Medicine.
Researchers from the United States and the Netherlands sought to evaluate the benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. The outcome measures included breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, biopsies recommended after a false-positive ultrasonography result, and costs.
"Our study is timely because with existing breast density notification laws in some 19 states, and with national legislation pending, it is critical that we understand what approaches to supplemental breast cancer screening are most effective for women with dense breasts," Anna Tosteson, ScD, of Dartmouth Hitchcock’s Norris Cotton Cancer Center and The Dartmouth Institute for Health Policy and Clinical Practice, said in a release.[[{"type":"media","view_mode":"media_crop","fid":"30440","attributes":{"alt":"Anna N. A. Tosteson, ScD","class":"media-image media-image-right","id":"media_crop_9045364651650","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3195","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Anna N. A. Tosteson, ScD","typeof":"foaf:Image"}}]]
The results showed that supplemental ultrasonography screening after a negative mammography for every 1,000 women who were aged from 50 to 74 and who had heterogeneously or extremely dense breasts, 0.36 additional breast cancer deaths were averted, 1.7 QALYs were gained, and there were 354 biopsy recommendations after a false-positive ultrasonography result, compared with biennial screening by mammography alone. “The cost-effectiveness ratio was $325,000 per QALY gained (range, $112,000 to $766,000 per QALY gained),” the authors wrote. “Supplemental ultrasonography screening for only women with extremely dense breasts cost $246,000 per QALY gained (range, $74,000 to $535,000 per QALY gained).”
The researchers concluded that using ultrasonography screening for women with dense breasts would substantially increase costs while producing relatively small benefits.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
Mammography Study: Can Stand-Alone AI Enhance Detection of Interval Breast Cancer?
August 28th 2024Identifying over 23 percent of interval breast cancers with a 96 percent sensitivity in mammography interpretation, an emerging AI software also facilitated correct localization in over 75 percent of cases involving interval breast cancer, according to new research.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.